Success Metrics

Clinical Success Rate
33.3%

Based on 1 completed trials

Completion Rate
33%(1/3)
Active Trials
3(50%)
Results Posted
100%(1 trials)
Terminated
2(33%)

Phase Distribution

Ph early_phase_1
1
17%
Ph phase_1
4
67%
Ph phase_2
1
17%

Phase Distribution

5

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Early Phase 1First-in-human
1(16.7%)
Phase 1Safety & dosage
4(66.7%)
Phase 2Efficacy & side effects
1(16.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

3

trials recruiting

Total Trials

6

all time

Status Distribution
Active(3)
Completed(1)
Terminated(2)

Detailed Status

Recruiting2
Terminated2
Completed1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
3
Success Rate
33.3%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (16.7%)
Phase 14 (66.7%)
Phase 21 (16.7%)

Trials by Status

recruiting233%
completed117%
active_not_recruiting117%
terminated233%

Recent Activity

3 active trials
Showing 5 of 6
terminatedphase_1

Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases

NCT05341349
recruitingphase_1

Preoperative Radiosurgery for the Treatment of High Grade Glioma, NeoGlioma Trial

NCT05030298
active_not_recruitingphase_1

Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer

NCT03203525
recruitingphase_1

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

NCT05092373
completedearly_phase_1

Temozolomide, Radiation Therapy, and Tumor Treating Fields Therapy in Treating Participants With Glioblastoma

NCT03477110
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT05341349Phase 1

Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases

Terminated
NCT05030298Phase 1

Preoperative Radiosurgery for the Treatment of High Grade Glioma, NeoGlioma Trial

Recruiting
NCT03203525Phase 1

Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer

Active Not Recruiting
NCT05092373Phase 1

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

Recruiting
NCT03477110Early Phase 1

Temozolomide, Radiation Therapy, and Tumor Treating Fields Therapy in Treating Participants With Glioblastoma

Completed
NCT03995667Phase 2

Tumor Treating Fields (TTFields) Therapy to Manage Brain Metastases in Small Cell Lung Cancer

Terminated

All 6 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
6